Cantor Fitzgerald Issues Negative Forecast for CRBU Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Cantor Fitzgerald lowered their FY2025 earnings estimates for Caribou Biosciences in a note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst R. Bienkowski now forecasts that the company will earn ($1.85) per share for the year, down from their prior estimate of ($1.31). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.35 million for the quarter, compared to analysts' expectations of $1.48 million.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $7.40.

Caribou Biosciences Trading Up 4.0%

Shares of NASDAQ:CRBU traded up $0.04 during trading on Wednesday, reaching $0.98. The stock had a trading volume of 394,507 shares, compared to its average volume of 1,510,089. The company has a market capitalization of $90.77 million, a P/E ratio of -0.59 and a beta of 2.36. The firm's 50-day simple moving average is $0.86 and its 200 day simple moving average is $1.42. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.45.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Centric Wealth Management acquired a new stake in Caribou Biosciences in the 4th quarter valued at $27,000. Russell Investments Group Ltd. boosted its position in shares of Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after acquiring an additional 21,416 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after buying an additional 9,148 shares during the period. Diametric Capital LP purchased a new stake in Caribou Biosciences in the 4th quarter valued at about $42,000. Finally, US Bancorp DE increased its stake in Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after purchasing an additional 26,467 shares during the period. Institutional investors and hedge funds own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.